March 2, 2020
Takeda Pharmaceutical said on February 28 that it has submitted a new drug application in Japan for the synthetic imidazobenzodiazepine derivative midazolam (development code: SHP615) for the treatment of status epilepticus. The product, which was developed by former Shire, has...read more